Rafael Holdings Operating Income Growth & History (RFL)
Rafael Holdings's operating income was −$29.2M for fiscal 2025.
View full Rafael Holdings company overviewRafael Holdings annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | −$29.2M | $73.5M | — |
| 2024 | 2024-07-31 | −$102.6M | −$87.6M | — |
| 2023 | 2023-07-31 | −$15.0M | $45.4M | — |
| 2022 | 2022-07-31 | −$60.5M | −$32.3M | — |
| 2021 | 2021-07-31 | −$28.2M | −$19.7M | — |
| 2020 | 2020-07-31 | −$8.5M | −$1.8M | — |
| 2019 | 2019-07-31 | −$6.7M | −$2.9M | — |
| 2018 | 2018-07-31 | −$3.8M | −$4.1M | — |
| 2017 | 2017-07-31 | $221,000 | −$971,000 | −81.46% |
| 2016 | 2016-07-31 | $1.2M | — | — |
Rafael Holdings quarterly operating income
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | −$6.9M | −$957,000 | — |
| Q2 2026 | 2026-01-31 | −$6.7M | −$16,000 | — |
| Q1 2026 | 2025-10-31 | −$10.1M | −$6.3M | — |
| Q4 2025 | 2025-07-31 | −$12.8M | −$8.9M | — |
| Q3 2025 | 2025-04-30 | −$5.9M | $87.2M | — |
| Q2 2025 | 2025-01-31 | −$6.6M | −$3.5M | — |
| Q1 2025 | 2024-10-31 | −$3.8M | −$1.4M | — |
| Q4 2024 | 2024-07-31 | −$3.8M | −$1.2M | — |
| Q3 2024 | 2024-04-30 | −$93.2M | −$90.1M | — |
| Q2 2024 | 2024-01-31 | −$3.1M | $1.1M | — |
| Q1 2024 | 2023-10-31 | −$2.5M | $2.7M | — |
| Q4 2023 | 2023-07-31 | −$2.6M | $2.0M | — |
| Q3 2023 | 2023-04-30 | −$3.0M | $1.7M | — |
| Q2 2023 | 2023-01-31 | −$4.3M | −$2.7M | — |
| Q1 2023 | 2022-10-31 | −$5.1M | $44.4M | — |
| Q4 2022 | 2022-07-31 | −$4.7M | — | — |
| Q3 2022 | 2022-04-30 | −$4.7M | −$1.2M | — |
| Q2 2022 | 2022-01-31 | −$1.6M | $9.2M | — |
| Q1 2022 | 2021-10-31 | −$49.5M | −$47.0M | — |
| Q3 2021 | 2021-04-30 | −$3.5M | −$1.5M | — |
| Q2 2021 | 2021-01-31 | −$10.8M | −$8.9M | — |
| Q1 2021 | 2020-10-31 | −$2.5M | −$949,000 | — |
| Q4 2020 | 2020-07-31 | −$3.1M | −$300,000 | — |
| Q3 2020 | 2020-04-30 | −$2.0M | −$547,000 | — |
| Q2 2020 | 2020-01-31 | −$1.9M | −$500,000 | — |
| Q1 2020 | 2019-10-31 | −$1.5M | −$422,000 | — |
| Q4 2019 | 2019-07-31 | −$2.8M | −$1.5M | — |
| Q3 2019 | 2019-04-30 | −$1.4M | −$687,000 | — |
| Q2 2019 | 2019-01-31 | −$1.4M | −$590,000 | — |
| Q1 2019 | 2018-10-31 | −$1.1M | −$65,000 | — |
| Q4 2018 | 2018-07-31 | −$1.2M | −$1.3M | — |
| Q3 2018 | 2018-04-30 | −$731,000 | −$567,000 | — |
| Q2 2018 | 2018-01-31 | −$816,000 | −$943,000 | — |
| Q1 2018 | 2017-10-31 | −$1.1M | — | — |
| Q4 2017 | 2017-07-31 | $100,000 | — | — |
| Q3 2017 | 2017-04-30 | −$164,000 | — | — |
| Q2 2017 | 2017-01-31 | $127,000 | — | — |
Rafael Holdings operating income trends
Over the last five fiscal years, Rafael Holdings's operating income decreased from −$8.5M to −$29.2M, a change of −$20.7M. The latest reported quarter, Q3 2026, shows −$6.9M.
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rafael Holdings source filings ↗Community posts
Rafael submits remibetadex for FDA review despite a missed pivotal endpoint
Rafael Holdings ($RFL) said its Cyclo Therapeutics subsidiary submitted a US marketing application for remibetadex, also called Trappsol Cyclo, for neurological and internal-organ manifestations of Niemann-Pick disease type C. The proposed ...